As of 2024-12-11, the EV/EBITDA ratio of Altimmune Inc (ALT) is -6.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 609.32 mil USD. Altimmune's TTM EBITDA according to its financial statements is -98.88 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 16.6x | 15.0x |
| Forward P/E multiples | 15.1x - 17.8x | 15.9x |
| Fair Price | (20.58) - (22.61) | (21.07) |
| Upside | -328.4% - -350.9% | -333.9% |
| Date | EV/EBITDA |
| 2024-12-10 | -6.80 |
| 2024-12-09 | -6.62 |
| 2024-12-06 | -6.23 |
| 2024-12-05 | -6.26 |
| 2024-12-04 | -6.77 |
| 2024-12-03 | -6.00 |
| 2024-12-02 | -6.05 |
| 2024-11-29 | -5.85 |
| 2024-11-27 | -5.96 |
| 2024-11-26 | -5.75 |
| 2024-11-25 | -5.85 |
| 2024-11-22 | -5.92 |
| 2024-11-21 | -5.73 |
| 2024-11-20 | -5.47 |
| 2024-11-19 | -5.05 |
| 2024-11-18 | -4.82 |
| 2024-11-15 | -5.16 |
| 2024-11-14 | -5.76 |
| 2024-11-13 | -6.53 |
| 2024-11-12 | -6.51 |
| 2024-11-11 | -4.97 |
| 2024-11-08 | -5.21 |
| 2024-11-07 | -5.05 |
| 2024-11-06 | -4.94 |
| 2024-11-05 | -4.74 |
| 2024-11-04 | -4.57 |
| 2024-11-01 | -4.53 |
| 2024-10-31 | -4.53 |
| 2024-10-30 | -4.54 |
| 2024-10-29 | -4.98 |
| 2024-10-28 | -4.72 |
| 2024-10-25 | -4.49 |
| 2024-10-24 | -4.55 |
| 2024-10-23 | -4.52 |
| 2024-10-22 | -4.57 |
| 2024-10-21 | -4.64 |
| 2024-10-18 | -4.63 |
| 2024-10-17 | -4.57 |
| 2024-10-16 | -4.62 |
| 2024-10-15 | -4.75 |
| 2024-10-14 | -4.31 |
| 2024-10-11 | -4.21 |
| 2024-10-10 | -4.01 |
| 2024-10-09 | -4.08 |
| 2024-10-08 | -4.17 |
| 2024-10-07 | -4.07 |
| 2024-10-04 | -4.16 |
| 2024-10-03 | -4.11 |
| 2024-10-02 | -4.19 |
| 2024-10-01 | -4.21 |